ClinicalTrials.gg
RecruitingNCT07830407Updated Sep 21, 2026

Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer

An observational study in Colorectal Cancer, sponsored by Pierian Biosciences. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Pierian Biosciences · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 388 studies in Colorectal Neoplasms with a site in United Kingdom — 72 open to participants now, 100 under way, 18 of them phase 3. Colorectal Neoplasms · United Kingdom.

Planned enrollment
57th of 80
100 · median 275
Started
2026
with 8 others
Observational
80 of 388
21 open now
Primary completion
2028-04
later than 68 of 99 live
Registered
388th of 388
by date

Among the 388 studies in Colorectal Neoplasms with a site in United Kingdom, this one is the 57th largest by planned enrollment of the 80 observational ones that give a count, is one of 9 that started in 2026, is one of 80 observational ones, reaches primary completion later than 68 of the 99 other live ones, and was the 388th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

72 of the 388 studies in Colorectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 388 studies in Colorectal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a prospective, non-randomized, observational, pre-clinical validation study. Pierian Biosciences is utilizing ChemoINTEL assay measured in vitro cytotoxic drug induced apoptosis and cell death in isolated fresh human tumour cells from patients with colorectal cancer (CRC) to predict a patient's tumour's sensitivity to specific chemotherapy drugs using the ChemoINTEL unified algorithm. Eligible patients will be assigned to one of three groups depending on the stage of disease :

Group 1: Patients who have colorectal cancer and are referred for adjuvant chemotherapy after MDT discussion.

Group 2: Patients with stage II colorectal cancer with high risk features not referred for adjuvant chemotherapy (at risk of relapse) Group 3: Patients with locally advanced rectal cancer who have had a complete response to chemoradiotherapy (research objective).

At least one solid tumour specimen and adjacent normal tissue will be sent to Pierian Biosciences Laboratory in Liverpool, UK along with an optional 10-20ml blood sample and The Pierian Biosciences laboratory staff will conduct the ChemoINTEL and ImmunoINTEL assays blinded to all specimen and clinical information except the tumor type (e.g. Colon Cancer or Rectal Cancer), Specimen ID, and specimen collection date and time. Results of the assay will NOT be shared with clinical sites. Samples from group 3 will be provided if patients undergo surgical resection.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • ChemoINTEL
  • Colorectal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Colorectal Cancer Diagnosis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years of age
  2. Diagnosis of CRC i. Surgical resection followed by chemotherapy ii. followed by neoadjuvant chemo/radiotherapy and surgical resection.
  3. Patients planned to receive at least 6 cycles of standard of care chemotherapy for CRC with single agent or combination of drugs listed in Table 3 following biopsy OR surgical resection
  4. One solid tumor specimen is required; a total of two specimens are preferred and requested when available. Specimens will include:

    i. Primary solid tumor specimen (≥400 mg) ii. Adjacent normal tissue (>400mg)

  5. Patient signed Form

Exclusion criteria

Exclusion Criteria Group 1 Participants:

  1. Patient has not signed an ICF to participate in a clinical investigation
  2. Patient has a cancer other than advanced stage CRC
  3. Patient is NOT expected to receive SOC chemotherapy, single agents or combination treatment, as listed in Table 3
  4. Patients who do not have at sufficient viable cells recovered from fresh tumor dissociation available for the ChemoINTEL assay analysis of Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Capecitabine
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group 1

    Patients who have colorectal cancer and are referred for surgical resection with adjuvant chemotherapy after MDT discussion

  • Group 2

    Patients with stage II colorectal cancer with high risk features referred for surgical resection but not referred for adjuvant chemotherapy (at risk of relapse)

  • Group 3

    Patients with locally advanced rectal cancer who have had a complete response to chemoradiotherapy (research objective)

06

What researchers measure

Primary outcomes

  1. Primary Objective

    To evaluate Group 1 ChemoINTEL Assay Unified Algorithm's prediction accuracy of clinical response to chemotherapy in patients with minimal residual colorectal cancer disease detectable by ctDNA post-surgery (prior to Cycle 1 chemotherapy) using patient response assessed by ctDNA measured 4 weeks post chemotherapy completion

    Time frame: Approximately 4 weeks post chemotherapy completion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Plan to disseminate the findings and publish the findings, all data will be anonymised

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 24 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 21, 2026
StartActual
Apr 21, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2030
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07830407
Lead sponsor
Pierian Biosciences
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Apr 21, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2030 (estimated)
Last update
Sep 21, 2026

Study contacts

Norman B Purvis, PhD
Contact
npurvis@pierianbio.com
+44 (0)333 034 1690
Robert Henry
Contact
rhenry@pierianbio.com
+1 (615) 567-0200
Rosemary Lord, PhD FRCP
principal investigator · Clatterbridge Cancer Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion